SEC Delivers Report to Congress with Recommendations from 40th Annual Small Business Forum

Washington D.C., Sept 27, 2021 — Today the Office of the Advocate for Small Business Capital Formation delivered a report to Congress on the Securities and Exchange Commission’s 40th Annual Small Business Forum. The 2021 Forum took place virtually on May 24–27, 2021, with each session featuring panelists with in-depth knowledge of the issues facing small businesses across the country, spotlighting the following topics:

  • Monday, May 24: Finding Your First Dollars: Navigating Your Way to Raise Early Rounds
  • Tuesday, May 25: Doing Your Diligence: How Savvy Early-Stage Investors Build Diversified Portfolios
  • Wednesday, May 26:  Diversifying Capital Allocators: Tools for Emerging and Smaller Funds and Their Managers
  • Thursday, May 27:  Small Cap Insights: Perspectives on Smaller Public Companies

The report provides a summary of the Forum proceedings, including the recommendations developed by participants for changes needed to the capital raising framework and the Commission’s responses to the recommendations. Continue reading

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib

August 25, 2021– Palo Alto, California & Shanghai & Princeton, New Jersey (Business Wire) — LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification and other advanced solid tumors with FGFR genomic alterations.

“We believe that infigratinib could have a meaningful impact for people living with gastric cancer as well as many other cancers with FGFR alterations, and are pleased LianBio is initiating this clinical trial in China where more therapeutic options are needed to match the growing diagnosis rate.”

“Infigratinib is a potent and selective FGFR inhibitor that has demonstrated compelling clinical activity across multiple tumor types with FGFR alterations,” said Yizhe Wang, Ph.D., chief executive officer of LianBio. “Given the disproportionately high prevalence rate of gastric cancer in China, LianBio is pursuing a region-specific development strategy focused on this area of great unmet need. This study marks LianBio’s first trial initiation and demonstrates our continued progress in delivering potentially transformational medicines to patients in Asia.” Continue reading

6 Things Every American Needs And Deserves!

While, we have always, witnessed, partisan – politics, in some forms, in this nation, it seems, in recent memory, never, to the degree, we see it, today! When, this behavior, transforms itself, into, being, obstructionists, and, little, of consequence, seems to get achieved, and/ or, even, addressed, doesn’t that seem, to be, concerning, the quality future, the generations – to – follow, need and deserve? When nearly, every American, needs and deserves, certain things, and, politics, interferes, we must address this, sooner, rather than later! With, that in mind, this article will attempt to, briefly, consider, examine, review, and discuss, 6 specific things/ areas, which must be addressed, in a well – considered, timely manner.

1. Access to affordable medicine: Although,we like to pride – ourselves, on our health – care, system, the data, says something, different! In, nearly, every area/ analysis, we are, at – best, middle – of – the – road, in how we treat, the health of our people! Why are we, the only, major nation, where access to quality care, depends on one’s personal finances, etc? Why is the cost of prescription drugs, so much higher, than the rest – of – the – world? Why is medical/ health insurance, so costly, and limiting? Shouldn’t quality health care be a right, rather than, simply, a privilege, to the few? Continue reading

Americaweb.org